Related Experiment Videos
Blood--its derivatives and its problems--factor VIII
Annals of the New York Academy of Sciences
|January 20, 1975
Summary
Despite advances in factor VIII concentrates, hemophilia patients still face arthritis, employment issues, and premature death. Prophylactic programs could significantly ease long-term physical and psychological disabilities for severe cases.
Area of Science:
- Hematology
- Internal Medicine
Background:
- Concentrated factor VIII products have improved hemophilia management.
- However, significant challenges remain for patients despite advanced treatments.
Purpose of the Study:
- To highlight persistent issues faced by hemophiliacs.
- To advocate for solutions addressing hepatitis transmission, availability, and cost of factor VIII.
- To propose prophylactic programs for severely affected patients.
Main Methods:
- This abstract does not detail specific methods.
- It presents a qualitative overview of patient challenges and treatment limitations.
Main Results:
- Hemophilia patients continue to experience debilitating arthritis.
- Employment difficulties, lack of medical and public understanding, and increased mortality persist.
- Hepatitis transmission, product availability, and economic factors are critical unresolved issues.
Conclusions:
- Concentrated factor VIII is insufficient to resolve all hemophilia-related problems.
- Addressing hepatitis, availability, and cost is crucial for equitable treatment.
- Prophylactic regimens are recommended to mitigate long-term psychologic and physical sequelae in severe hemophilia.